DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.

Information source: Central Hospital, Nancy, France
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ischemic Stroke

Intervention: Aspirin (Drug); blood sample (Biological)

Phase: N/A

Status: Recruiting

Sponsored by: Central Hospital, Nancy, France

Overall contact:
Sébastien Richard, MD, Phone: 3 83 85 16 56, Ext: 0 33, Email: s.richard@chu-nancy.fr

Summary

Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic event. The principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences. Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23 hours after. Photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.

Clinical Details

Official title: Laboratory Effect on Platelet Activity of the First 300 mg Oral Dose Aspirin at the Acute Phase of Cerebral Ischemic Event.

Study design: Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Measure of platelet activity recovery within 24 hours after the first 300 mg oral dose of aspirin given at hospital at the acute phase of ischemic stroke

Secondary outcome: Measure of effect of the first 300 mg oral dose of aspirin given at the acute phase of cerebral ischemic stroke for already aspirin treated

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult men and women

- Ischemic stroke less than 48 hours

- Signed consent

Exclusion Criteria:

- Danger to prescription of aspirin (haemorrhagic risk...)

- Prescription of heparin or VKA

Locations and Contacts

Sébastien Richard, MD, Phone: 3 83 85 16 56, Ext: 0 33, Email: s.richard@chu-nancy.fr

Hopital central, Nancy 54035, France; Recruiting
Sébastien Richard, MD, Phone: 3 83 85 16 56, Ext: 33 0, Email: s.richard@chu-nancy.fr
Sébastien Richard, MD, Principal Investigator
Additional Information

Starting date: December 2010
Last updated: June 20, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017